Grants and Contributions:
Title:
Elarex Viral Vectored Exosomal Vaccine Development and Stabilization
Agreement Number:
998641
Agreement Value:
$102,000.00
Agreement Date:
Sep 1, 2022 - Mar 31, 2023
Description:
Optimization of ultra-stable formulation for viral vectored vaccine, compatible with oral dosing
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burlington, Ontario, CA L7L 4X5
Reference Number:
172-2022-2023-Q3-998641
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
756228474
Recipient Type:
For-profit organization
Recipient's Legal Name:
Elarex Inc.
Federal Riding Name:
Burlington
Federal Riding Number:
35015
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171